Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Published
Biogen Inc BIIB is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval. Biogen said on Wednesday it would discontinue developing and commercializing Aduhelm (aducanumab-avwa) 100 mg/mL…
#biogenincbiib #aduhelmalzheimers #fda #biogen #aduhelm #leqembi #eisai #aso #neurimmune #priceaction